Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
363 Results Found
AHA Letter Re: MedPAC’s Draft Recommendations on IME And Outpatient Drug Payments
The AHA asks that commissioners consider the following issues as they recommend changes that would have a significant impact on hospitals, health systems and the Medicare patients we serve.
AHA Expresses Support for Legislation S. 773
AHA letter to Senators, John Thune, Rob Portman, Shelley Moore Capito, Tammy Baldwin, Debbie Stabenow and Ben Cardin expressing support for legislation, S. 773.
Fact Sheet: 340B Drug Pricing Program Contract Pharmacy Arrangements
The Issue:
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health ca
Health Insurer Specialty Pharmacy Policies Threaten Patient Quality of Care
Regulators should prohibit health insurers from preventing hospitals and physicians in their networks from directly acquiring and storing drugs used in patient care. A number of large health insurers are requiring these providers to accept drugs purchased or handled by their own or affiliated pharmacies.
AHA blog: PhRMA report misleads on drug costs
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs for Americans, writes AHA Executive Vice President Tom Nickels.
PhRMA report misleads on drug costs
America’s hospitals and health systems, and our heroic caregivers, have been on the front lines of the battle against COVID-19 for the past year, working tirelessly to provide needed care to patients and communities.
AHA urges CMS to withdraw Most Favored Nation rule
AHA today urged the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and “replace it with a serious effort at drug pricing reform.”
AHA Urges CMS to Withdraw Most Favored Nation Rule
AHA urges the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and “replace it with a serious effort at drug pricing reform.
AHA Statement on Court Delay of Most Favored Nation Model Interim Final Rule
AHA statement on court delay of most favored nation model interim final rule from Executive Vice President Tom Nickels.
AHA 340B Advocacy Alliance Bulletin: Attorneys general urge HHS to hold responsible drug manufacturers not providing 340B discounts
Attorneys general in 27 states and Washington, D.C., today